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thelium with an annual incidence of 1-2 cases 
per 100,000 people but it is a potentially lethal 
disease.1-3 Despite intense collaborative efforts 
Upper tract urothelial carcinoma (UTUc) is a rare disease that accounts for approxi-
mately 5% of all tumors derived from the uro-
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a B S T r a c T
BacKgroUnD: radical nephroureterectomy (rnU) with bladder cuff excision (Bce) is the surgical principle adopted 
for the treatment of upper tract urothelial cancers (UTUcs). However, not all rnUs are performed with Bce. We quanti-
fied the prognostic impact of RNU with BCE on cancer-specific survival (CSS) in a large patient population.
MeTHoDS: in total, 505 patients with UTUc were enrolled from four different institutions. The clinicopathological 
parameters of patients who underwent rnU with and without Bce were compared. The Kaplan–Meier and multivariate 
Cox regression analyses were performed to assess the influence of BCE on CSS.
reSUlTS: in total, 60 (11.9%) patients had not undergone Bce during rnU. compared to patients who underwent 
Bce, these patients were older and had more comorbidities. Patients with UTUc who had not undergone Bce were more 
likely to be associated with ≥pT3, margin positivity, and renal pelvis localization compared to patients who underwent 
Bce. Median follow-up periods were 30.5 months (range, 6-144 months). The Kaplan-Meier estimates revealed that 
BCE during RNU was not significantly associated with CSS in all UTUC patients and in the subgroup with renal pelvis 
localization; however, patients who underwent RNU without BCE had significantly worse CSS rates compared to patients 
who underwent RNU with BCE in the subgroup analysis of patients with ureteral cancer. Multivariate analysis identified 
Bce as an independent prognostic factor of cSS in patients with ureteral cancer.
CONCLUSIONS: In the present study, RNU without BCE resulted in significantly worse CSS in ureteral cancer patients, 
which indicated that Bce should be mandatory in patients with ureteral cancer.
(Cite this article as: Ha YS, chung JW, choi SH, lee Jn, Kim BS, Kim TH, et al. impact of a bladder cuff excision during 
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sity, Daegu, South Korea (KnUMc 2016-05-
021). The study was carried out in agreement 
with the applicable laws and regulations, good 
clinical practices, and ethical principles as 
described in the Declaration of Helsinki. The 
board exempted informed consent because it 
was a retrospective study.
Study population
a database of 505 patients with UTUc who 
underwent either open or laparoscopic rnU 
between 2001 and 2013 at four academic cen-
ters was reviewed. The patient characteris tics 
included in the database were the age, sex, 
Body Mass index, history of bladder cancer, 
pre-operative american Society of anesthe-
siologists physical status score, surgical ap-
proach (open vs. laparoscopic), tumor pathol-
ogy (stage, grade, lymph node status, and 
lymphatic vessel invasion), tumor necrosis, 
concomitant carcinoma in situ, tumor location, 
use of adjuvant chemotherapy, unifocal or mul-
tifocal disease, disease recurrence or metasta-
sis, and mortality from urothelial carcinoma. 
The complete follow-up data were available 
for all patients and were therefore included in 
the analysis. after combining the datasets, re-
ports were generated for each variable to iden-
tify the inconsistencies in the data along with 
other data integrity problems. Before the final 
analysis, the database was frozen, and the final 
dataset was generated. in order to avoid bias in 
the survival estimates, patients who had pre-
vious or concomitant muscle-invasive bladder 
tumors treated by cystectomy were excluded. 
Patients with distant metastases at diagnosis 
and those who received neoadjuvant therapy 
were also excluded. all patients underwent 
preoperative cystoscopy, urine cytology, and 
chest and abdominal-pelvic computed tomog-
raphy.
Surgical techniques
Surgery was performed according to the 
standard rnU protocol that includes the ex-
trafascial dissection of the kidney along with 
the entire length of the ureter and the adja-
to improve the knowledge on this disease, its 
management remains challenging.4, 5 in pa-
tients with a normal contralateral kidney, radi-
cal nephroureterectomy (rnU) with bladder 
cuff excision (Bce) is the gold standard treat-
ment for UTUc.6, 7 However, not all rnUs are 
performed with a Bce. according to a previous 
multi-institutional tertiary care center study, a 
substantial portion of the patients who under-
went rnU (711/1249, 56.9%) did not undergo 
Bce.8 Moreover, urologists have disputed 
whether they should always perform Bce dur-
ing rnU since the in troduction of minimally in-
vasive surgery.9 Tumor recurrence in a retained 
ureteral segment after imperfect rnU is an im-
portant dilemma and may contribute to bladder 
recurrence or metastasis.10 oncologic outcome 
is a considerable issue for patients who undergo 
rnU with or without Bce. Many studies have 
shown poor oncologic outcomes in patients who 
underwent rnU without Bce, whereas some 
studies have reported comparable outcomes be-
tween the two surgical approaches.8, 11-13
in some cases, we had not performed Bce 
during rnU owing to several inevitable rea-
sons. for example, surgeons omitted Bce 
in elderly patients or in patients having mul-
tiple comorbidities, for whom the operation 
had to be completed in a short time. in cases 
of patients who had aggressive tumors in the 
involved ureters with distal parts highly ad-
hesive to the adjacent organs, surgeons failed 
to approach the end of the ipsilateral ureters 
near the bladder due to technical challeng-
es and therefore they omitted Bce. To date, 
there have not been any definitive conclusions 
concerning the prognostic value of Bce in 
the Korean UTUc patient cohort. Therefore, 
we compared the clinical characteristics and 
cancer-specific survival (CSS) between UTUC 
patients who underwent rnU with and with-
out Bce in a large, multi-institutional study.
Materials and methods
Ethics statement
This study was approved by the institutional 
review board at Kyungpook national Univer-
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confounders. all statistical analyses were per-
formed using the SPSS software version 18.0 
(SPSS inc., chicago, il, USa). all reported 
P values were two-sided, and all P<0.05 were 
considered statistically significant.
Results
The study population consisted of 505 pa-
tients with UTUc who underwent rnU with 
(445/505, 88.1%) and without (60/505, 11.9%) 
Bce. compared to patients who underwent 
Bce, patients who did not undergo Bce were 
older (P<0.001) and had a higher american 
Society of anesthesiologists performance sta-
tus score (P=0.009; Table i). UTUc treated 
without Bce was more likely to be associated 
with pathologic stage ≥T3 than UTUC treated 
with Bce (P=0.026). Patients who did not 
undergo Bce had higher potential of surgi-
cal margin positivity than that of patients who 
underwent Bce (P=0.001). compared to the 
tumors of patients treated with Bce, those of 
patients treated without Bce were more fre-
quently localized to the renal pelvis (P=0.001). 
other clinicopathological features were simi-
lar between the two groups (Table i).
During the follow-up (median, 30.5 months; 
range, 6-144 months), 173 patients (34.3%) 
experienced intravesical recurrence and 137 
patients (27.1%) developed locoregional recur-
rence/distant metastasis. There were no signif-
icant differences in the intravesical recurrence-
free survival and local/distant metastasis-free 
survival between patients who underwent and 
did not undergo Bce even in subgroup analy-
ses of renal pelvic tumor and ureteral cancer. 
in total, 111 patients (22.0%) died during the 
follow-up. of the 111 patients who died, the 
deaths of 88 patients (17.4%) were UTUc 
related. The Kaplan-Meier estimates for cSS 
are demonstrated in figure 1. The log-rank 
analysis revealed that Bce during rnU was 
not significantly associated with CSS in all 
UTUc patients and in the subgroup of renal 
pelvis cancer; however, Kaplan-Meier analy-
sis revealed that patients who underwent rnU 
without BCE had significantly worse CSS 
rates than patients who underwent rnU with 
cent segment of the bladder cuff. Bce was 
performed according to the standard protocol 
(i.e., using an extravesical approach involving 
a gibson incision) as stipulated by each center. 
The hilar and regional lymph nodes adjacent 
to the ipsilateral great vessel were generally 
resected if they were palpable intraoperatively 
or if they were enlarged on preoperative axial 
imaging. The extent of lymphadenectomy per-
formed was at the discretion of the individual 
surgeons. Majority of the patients with non-or-
gan-confined diseases received cisplatin-based 
adjuvant chemotherapy. Tumors were staged 
according to the 6th edition of the american 
Joint committee on cancer staging system,14 
and the tumor grades were assessed according 
to the 1998 World Health organization clas-
sification system.15
Follow-up
each patient was followed up according to 
the standard protocol. in general, patients were 
followed up every 3-4 months during the first 
year following rnU, every 6 months in years 
2-5, and annually thereafter. The follow-up 
consisted of taking the patient history, physical 
examination, routine blood and serum chemis-
try tests, urinary cytology, chest radiography, 
cystoscopic evaluation of the urinary bladder, 
and radiographic evaluation of the contralat-
eral upper urinary tract. elective bone scans, 
chest computed tomography scans, and mag-
netic resonance imaging were performed when 
clinically indicated. Time to cSS was calcu-
lated as the time from surgery to the date of 
cancer-related mortality.
Statistical analysis
categorical variables were compared using 
the Pearson χ2 or fisher exact tests and con-
tinuous variables were compared using the 
Student t-test. The probability of survival was 
calculated using the Kaplan-Meier method, 
and statistical differences were evaluated us-
ing the log-rank test. Multivariate analysis was 
performed using the cox proportional haz-
ards model adjusted for the effect of potential 
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stage, there were no significant differences in 
intravesical recurrence-free survival, local/dis-
tant metastasis-free survival and cSS between 
Bce (log-rank test, P=0.024) in the subgroup 
analysis of patients with ureteral cancer. When 
we performed subgroup analyses according to 
Table I.—Clinicopathological characteristics of patients with and without bladder cuff excision.
Parameters Patients without bladder cuff excision (n.=60)
Patients with bladder 
cuff excision (n.=445) P
age (years, mean±SD) 72.0±9.6 65.5±10.4 <0.001
BMi (kg/m²) 23.4±2.7 23.8±3.1 0.365
Sex, n. (%) 0.137
Men 36 (60.0) 312 (70.1)
Women 24 (40.0) 133 (29.9)
Smoking status, n. (%) 0.152
no 44 (73.3) 283 (63.6)
Yes 16 (26.7) 162 (36.4)
aSa score, n. (%) 0.009
1 6 (10.0) 114 (25.6)
2-4 54 (90.0) 331 (74.4)
laterality, n. (%) 0.584
left 34 (56.7) 234 (52.6)
right 26 (43.3) 211 (47.4)
operative method 0.319
open 18 (30.0) 165 (37.1)
laparoscopic 42 (70.0) 280 (62.9)
Tumor size (mm, mean±SD) 47.3±37.5 37.5±23.6 0.056
Tumor location, n. (%) 0.001
renal pelvis 33 (55.0) 152 (34.2)
Ureter 16 (26.7) 236 (53.0)
Both 11 (18.3) 57 (12.8)
Previous or synchronous nMiBc, n. (%) 0.485
no 46 (76.7) 362 (81.3)
Yes 14 (23.3) 83 (18.7)
Multifocality, n. (%) 0.233
no 37 (61.7) 312 (70.1)
Yes 23 (38.3) 133 (29.9)
Pathologic T stage, n. (%) 0.026
Ta, ciS, T1–2 27 (45.0) 268 (60.2)
T3−4 33 (55.0) 177 (39.8)
Pathologic n. stage, n. (%) 0.748
nx 27 (45.0) 191 (42.9)
n0 29 (48.3) 230 (51.7)
n.+ 4 (6.7) 24 (5.4)
grade, n. (%) 0.533
low 18 (30.0) 115 (40.2)
High 42 (70.0) 330 (59.8)
concomitant ciS, n. (%) 0.291
no 58 (96.7) 401 (92.2)
Yes 2 (3.3) 34 (7.8)
lymphovascular invasion, n. (%) 0.110
no 44 (73.3) 367 (82.5)
Yes 16 (26.7) 78 (17.5)
Margin status, n. (%) 0.001
negative 54 (90.0) 425 (95.5)
Positive 6 (10.0) 20 (4.5)
adjuvant chemotherapy, n. (%) 0.493
no 45 (75.0) 351 (78.9)
Yes 15 (25.0) 94 (21.1)
nMiBc: non-muscle-invasive bladder cancer; UTUc: upper tract urothelial carcinoma; ciS: carcinoma in situ; SD: standard deviation; BMi: 
Body Mass index; aSa: american Society of anesthesiologists.
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grade tumors, patients without Bce had worse 
local/distant metastasis-free survival and cSS 
(figure 3).
We further evaluated the clinicopathologi-
cal characteristics of ureteral cancer in patients 
patients who underwent and did not undergo 
Bce stratifying by stage (figure 2). in high 
grade tumors, bladder recurrence had a sig-
nificant difference between patients with BCE 
and those without (figure 3). among the low 
Figure 1.—Kaplan-Meier curves for cancer-specific survival according to bladder cuff management. A) All patients; B) ure-
teral cancer subgroup; c) renal pelvis tumor subgroup.
Figure 2.—Kaplan-Meier curves for intravesical recurrence-free survival (A), metastasis free survival (B) and cancer specific 
survival (c) according to bladder cuff management stratifying by stage.
Bce: bladder cuff excision.
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treatment of UTUc.3 However, not all rnUs 
are performed with Bce. Moreover, there 
have not been any definitive conclusions con-
cerning the prognostic value of Bce in the Ko-
rean UTUc patient cohort. in order to address 
the effect of BCE on the rate of cancer-specific 
mortality, we performed a multi-institutional 
study in patients with UTUc who were treated 
with rnU. our observations revealed two im-
portant findings.
first, the patients who underwent rnU with-
out Bce were older, had more comorbidities, 
and tumors with higher pathologic stage that 
were localized to the renal pelvis. Therefore, 
some of the patients were ineligible to undergo 
Bce owing to inevitable reasons. it is also 
noteworthy that although Bce improves sur-
vival, it may increase morbidity. for example, 
during open or laparoscopic operation, Bce 
may require a second incision. furthermore, 
this procedure requires more time and wider 
dissection and increases the complexity of sur-
who underwent rnU with and without Bce. 
among the patients with ureteral cancer, there 
were no significant differences in the clini-
copathological parameters except the surgi-
cal margin status (P=0.010) between the two 
groups (Table ii). Multivariate analysis identi-
fied BCE (hazard ratio, 0.232 [95% confidence 
interval, 0.075-0.717]; P=0.011) as an inde-
pendent prognostic factor of cSS in patients 
with ureteral cancer (Table iii).
Discussion
UTUc cells can spread via the urine and 
seed in the underlying urothelium of the entire 
urinary tract.16 Because of these unique fea-
tures, patients who undergo simple nephrec-
tomy for UTUc have high recurrence rates 
of 33-70% in the remaining ureteral stump.17 
rnU with Bce, including the intramural por-
tion and the orifice of the ipsilateral ureter, is 
the current standard surgical approach for the 
figure 3.—Kaplan-Meier curves for intravesical recurrence-free survival (a), metastasis-free survival (B) and cancer-specif-
ic survival (c) according to bladder cuff management stratifying by grade.
Bce: bladder cuff excision.
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ureteral cancer. in general, renal pelvis tumor 
has a more favorable prognosis than ureter tu-
mor. The reason is that ureteral wall is thin and 
easy to invade to adjacent area. Based on these 
results, Bce should be mandatory in these pa-
tients. conversely, in patients with renal pel-
vic tumors, Bce omission does not undermine 
survival. Patients with incomplete nephro-
gery. Therefore, surgeons used to omit Bce, 
while performing a surgery for older adult pa-
tients or those having multiple comorbidities. 
However, to the best of our knowledge, the 
added morbidity has not been formally quanti-
fied.
Second, we confirmed the gain of survival 
benefit conferred by BCE only in patients with 
Table II.—Clinicopathological characteristics of ureteral cancer patients with and without bladder cuff excision.
Parameters Patients without bladder cuff excision (n.=27)
Patients with bladder 
cuff excision (n.=293) P
age (years, mean±SD) 72.0±8.7 66.6±10.4 0.067
BMi (kg/m²) 23.9±2.4 23.9±3.2 0.968
Sex, n. (%) 0.523
Men 16 (59.3) 197 (67.2)
Women 11 (40.7) 96 (32.8)
Smoking status, n. (%) 1.000
no 19 (70.4) 202 (63.1)
Yes 8 (29.6) 91 (28.9)
aSa score, n. (%) 0.054
1 2 (7.4) 71 (24.2)
2-4 25 (92.6) 222 (75.6)
laterality, n. (%) 0.428
left 16 (59.3) 149 (50.9)
right 11 (40.7) 144 (49.1)
operative method 0.533
open 12 (44.4) 107 (36.5)
laparoscopic 15 (55.6) 186 (63.5)
Tumor size (mm, mean±SD) 52.4±49.6 35.6±22.2 0.092
Previous or synchronous nMiBc, n. (%) 0.228
no 18 (66.7) 229 (78.2)
Yes 9 (33.3) 64 (21.8)
Multifocality, n. (%) 0.059
no 13 (48.1) 196 (66.9)
Yes 14 (51.9) 97 (33.1)
Pathologic T stage, n. (%) 0.095
Ta, ciS, T1-2 13 (48.1) 191 (65.2)
T3-4 14 (51.9) 102 (34.8)
Pathologic n stage, n. (%) 0.750
nx 10 (37.0) 128 (43.7)
n0 15 (55.6) 150 (51.2)
n.+ 2 (7.4) 15 (5.1)
grade, n. (%) 0.254
low 4 (14.8) 74 (25.3)
High 23 (85.2) 219 (74.7)
concomitant ciS, n. (%) 0.762
no 25 (92.6) 265 (90.4)
Yes 2 (7.4) 28 (9.6)
lymphovascular invasion, n. (%) 0.290
no 20 (74.1) 243 (82.9)
Yes 7 (25.9) 50 (17.1)
Margin status, n. (%) 0.010
negative 21 (77.8) 275 (93.9)
Positive 6 (22.2) 18 (6.1)
nMiBc: non-muscle-invasive bladder cancer; UTUc: upper tract urothelial carcinoma; ciS: carcinoma in situ; SD: standard deviation; BMi: 
Body Mass index; aSa: american Society of anesthesiologists.
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particularly ureteral cancer. in subgroups of 
ureteral cancer, BCE had a significant impact 
on cSS. Therefore, Bce should invariably be 
performed in patients with ureteral cancer.
Limitations of the study
The present study had several limitations. 
first, the comparison was not balanced. rnU 
with Bce is a standard operation for UTUc. 
When we had not performed Bce, there were 
several inevitable reasons although it is against 
oncological principles. Therefore the study 
population of this group cannot be large. Sec-
ond, it is limited by its retrospective nature and 
missing data as well as the heterogeneity of the 
patient population, variations in the follow-up 
schedule of each institution, and short median 
follow-up duration. However, when the data 
were reanalyzed by including the information 
on the institution, the statistical significance 
of the variables did not change, and the insti-
tutional differences did not affect disease re-
currence or mortality following rnU. Third, 
unfortunately, our database did not contain de-
tailed ureteral cuff management. So we did not 
know exactly how much of the ureteric stump 
was left. lastly, the absence of data on ureteral 
stump recurrences prevented us from conclud-
ing that rnU without Bce should represent 
a standard of care for all patients with renal 
pelvic tumors. Most patients who did not un-
ureterectomy are at increased risk for bladder 
cancer and potentially decreased survival;18 
however, Bce did not affect bladder recur-
rence in the present series. Kang et al. showed 
that patients who did not undergo Bce had 
poorer overall survival and cSS after rnU 
than those who underwent Bce.19 in a Korean 
study by Kim et al., bladder cuffing was the 
sole independent prognostic factor for disease 
specific survival among patients with stage III 
or iv UTUc.20 lughezzani et al. evaluated the 
prognostic significance of BCE during RNU 
for cSS in a large-scale population-based 
cohort of patients with renal pelvic tumors.12 
They showed that there was no increase in 
cancer-related death in patients with local-
ized (pT1-2n0/x) renal pelvic tumors when 
Bce was omitted and that cSS might decrease 
significantly if BCE was not performed in pa-
tients with locally advanced (pT3-4n0/x and 
pT[any]N1-3) renal pelvic tumors. In the pres-
ent study, there were no significant differences 
in intravesical recurrence-free survival, local/
distant metastasis-free survival and cSS be-
tween patients who underwent and did not un-
dergo Bce stratifying by stage. although we 
did not know exact reasons, ethnic differences 
may affect these results. This information may 
help patient categorization and indicate rnU 
without BCE in specific patients. The results 
of the present study provided useful informa-
tion for the management of UTUc patients, 
Table III.—Multivariate Cox regression analysis of the predictors of cancer related death in ureteral cancer.
Parameters Hr
95% ci
P
lower Upper
age 1.124 1.051 1.203 0.001
Sex (men vs. women) 1.114 0.370 3.357 0.848
Smoking (no vs. yes) 1.046 0.331 3.302 0.939
aSa score (1 vs. 2-4) 0.692 0.234 2.052 0.507
Pathologic T stage (Ta, ciS, T1-2 vs. T3-4) 3.711 1.116 12.337 0.032
Pathologic n stage (nx, n0 vs. n+) 15.673 4.621 53.159 <0.001
grade (low vs. high) 2.053 0.228 18.466 0.521
lymphovascular invasion (no vs. yes) 2.080 0.654 6.613 0.215
Multifocality (no vs. yes) 2.161 0.802 5.826 0.128
Bladder cuff excision (no vs. yes) 0.232 0.075 0.717 0.011
Margin status (no vs. yes) 0.914 0.259 3.223 0.888
Previous or synchronous nMiBc (no vs. yes) 1.141 0.410 3.174 0.800
concomitant ciS (no vs. yes) 1.982 0.392 10.033 0.408
nMiBc: non-muscle-invasive bladder cancer; UTUc: upper tract urothelial carcinoma; ciS: carcinoma in situ; BMi: Body Mass index; aSa: 
American Society of Anesthesiologists; HR: hazard ratio; CI: confidence interval.
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 6. Kang HW, Jung HD, Ha YS, Kim TH, Kwon Tg, Byun 
SS, et al. Preoperative underweight patients with upper 
tract urothelial carcinoma survive less after radical neph-
roureterectomy. J Korean Med Sci 2015;30:1483-9.
 7. Kim BW, Ha YS, lee Jn, Kim HT, Kim TH, lee JK, 
et al. effects of previous or synchronous non-muscle 
invasive bladder cancer on clinical results after radical 
nephroureterectomy for upper tract urothelial carcinoma: 
a multi-institutional study. Urol J 2015;12:2233-9.
 8. capitanio U, Shariat Sf, isbarn H, Weizer a, remzi M, 
roscigno M, et al. comparison of oncologic outcomes 
for open and laparoscopic nephroureterectomy:a multi-
institutional analysis of 1249 cases. eur Urol 2009;56:1-
9.
 9. Srirangam SJ, van cleynenbreugel B, van Poppel H. 
laparoscopic nephroureterectomy: the distal ureteral di-
lemma. adv Urol 2009:316807.
10. abel eJ, fisher MB, Matin Sf, Kamat aM, Dinney cP, 
grossman HB. Delayed ureterectomy after incomplete 
nephroureterectomy for upper tract urothelial carcino-
ma: pathologic findings and outcomes. Int Braz J Urol 
2013;39:817-22.
11. Zlotta ar. Should urologists always perform a bladder 
cuff resection during nephroureterectomy, and which 
method should they use? eur Urol 2010;57:970-2.
12. lughezzani g, Sun M, Perrotte P, Shariat Sf, Jeldres c, 
Budaus l, et al. Should bladder cuff excision remain the 
standard of care at nephroureterectomy in patients with 
urothelial carcinoma of the renal pelvis? a population-
based study. eur Urol 2010;57:956-62.
13. lughezzani g, Jeldres c, isbarn H, Sun M, Shariat Sf, 
alasker a, et al. nephroureterectomy and segmental ure-
terectomy in the treatment of invasive upper tract urothe-
lial carcinoma:a population-based study of 2299 patients. 
eur J cancer 2009;45:3291-7.
14. greene fl. The american Joint committee on cancer: 
updating the strategies in cancer staging. Bull am coll 
Surg 2002;87:13-5.
15. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World 
Health organization/international Society of Urological 
Pathology consensus classification of urothelial (tran-
sitional cell) neoplasms of the urinary bladder. Bladder 
consensus conference committee. am J Surg Pathol 
1998;22:1435-48.
16. Booth cM, cameron KM, Pugh rc. Urothelial carci-
noma of the kidney and ureter. Br J Urol 1980;52:430-5.
17. Mccarron JP, Mills c, vaughn eD Jr. Tumors of the re-
nal pelvis and ureter: current concepts and management. 
Semin Urol 1983;1:75-81.
18. Hou cP, chang Pl, chen cl, lin YH, Tsui KH. Does ad-
equate bladder cuff excision impact outcomes in patients 
undergoing nephroureterectomy for upper tract urothelial 
carcinoma. chang gung Med J 2011;34:496-505.
19. Kang M, Jeong cW, Kwak c, Kim HH, Ku JH. The char-
acteristics of recurrent upper tract urothelial carcinoma 
after radical nephroureterectomy without bladder cuff 
excision. Yonsei Med J 2015;56:375-81.
20. Kim HS, lee JS, Jeong cW, Kwak c, Kim HH, Ku JH. 
adjuvant chemotherapy for locally advanced upper tract 
urothelial carcinoma: updated results of the Seoul na-
tional University Hospital experience. int Braz J Urol 
2015;41:1067-79.
dergo Bce experienced tumor recurrence at 
the remnant ureter.19 in a study by Kang et al., 
40.0% of the patients who underwent Bce 
experienced ureteral stump recurrence, which 
aggravated the patient prognosis.19 in the pres-
ent study, there were no significant differences 
in intravesical recurrence-free survival and 
local/distant metastasis-free survival between 
patients who underwent and did not undergo 
Bce even in subgroup analyses of renal pel-
vic tumors and ureteral cancer. radical surgery 
and adjuvant chemotherapy might give the 
therapeutic effects on these results.
Conclusions
Despite its limitations, the present study 
demonstrated that cSS might decrease sig-
nificantly in patients with ureteral cancer who 
did not undergo Bce. Therefore, Bce should 
become the standard of care during rnU in 
these patients. conversely, no decrease in 
the cSS was recorded in patients with renal 
pelvic tumors when Bce was omitted from 
the treatment. However, Bce should only be 
omitted in specific cases for which this option 
is inevitable.
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